Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?

References

• Turner RC, Millns H, Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ316, 823–828 (1998).
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Circulation106, 3143–3421 (2002).
   PubMed Web of Science ®Google Scholar
• Brunzell JD, Davidson M, Furberg CD et al. Lipoprotein management in patients with cardiometabolic risk. Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care31, 811–821 (2008).
   PubMed Web of Science ®Google Scholar
• Fruchart JC, Sacks F, Hermans MP et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am. J. Cardiol.102(Suppl. 10), 1K–34K (2008).
   Web of Science ®Google Scholar
• Taskinen MR. Diabetic dyslipidaemia; from basic research to clinical practice. Diabetologia46, 733–749 (2003).
   PubMed Web of Science ®Google Scholar
• Brunzell JD. Hypertriglyceridemia. N. Engl. J. Med.357, 109–117 (2007).
   Google Scholar
• Durrington PN. Triglycerides are more important in atherosclerosis than epidemiology has suggested. Atherosclerosis141(Suppl. 1), S57–S62 (1998).
   PubMed Web of Science ®Google Scholar
• Phillips AN and GD Smith. How independent are ‘independent’ effects? Relative risk estimation when correlated exposures are measured imprecisely. J. Clin. Epidemiol.44, 1223–1231 (1991).
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors collaboration; Di Angelantonio E, Sarwar N, Perry P et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA.302, 1993–2000 (2009).
   PubMed Web of Science ®Google Scholar
• Cohn JS. Postprandial lipemia and remnant lipoproteins. Clin. Lab. Med.26, 773–786 (2006).
   PubMed Web of Science ®Google Scholar
• Sarwar N, Sandhu MS, Ricketts SL et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet375, 1634–1639 (2010).
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Benn M, Schnohr P et al. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA298, 299–308 (2007).
   PubMed Web of Science ®Google Scholar
• van Dieren S, Nothlings U, van der Schouw YT et al. Non-fasting lipids and risk of cardiovascular disease in patients with diabetes mellitus. Diabetologia54, 73–77 (2010).
   Google Scholar
• Scott R, O’Brien R, Fulcher G et al.; Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with Type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care32, 493–498 (2009).
   PubMed Web of Science ®Google Scholar
• The ACCORD Study Group. Effects of combination lipid therapy in Type 2 diabetes mellitus. N. Engl. J. Med.362, 1563–1574 (2010).
   PubMed Web of Science ®Google Scholar
• Frikke-Schmidt R. Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischaemic heart disease in the general population. Atherosclerosis208, 305–316 (2010).
   Google Scholar
• Roden M. Mechanisms of disease: hepatic steatosis in Type 2 diabetes–pathogenesis and clinical relevance. Nat. Clin. Pract. Endocrinol. Metab.2(6), 335–348 (2006).
   PubMedGoogle Scholar
• Chan DC, Watts GF. Dyslipidaemia in the metabolic syndrome and Type 2 diabetes: pathogenesis, priorities, pharmacotherapies. Expert Opin. Pharmacother.12, 13–30 (2011).
   PubMed Web of Science ®Google Scholar
• Zilversmit DB. Atherosclerosis: a postprandial phenomenon. Circulation60, 473–485 (1979).
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Stender S, Kjeldsen K. Reduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall. Arteriosclerosis8, 421–428 (1988).
   Google Scholar
• Rapp JH, Lespine A, Hamilton RL et al. Triglyceride-rich lipoproteins isolated by selected-affinity anti-apolipoprotein B immunosorption from human atherosclerotic plaque. Arterioscler. Thromb. Vasc. Biol.14, 1767–1774 (1994).
   PubMedGoogle Scholar
• Proctor SD, Mamo JCL. Retention of fluorescent-labelled chylomicron remnants within the intima of the arterial wall – evidence that plaque cholesterol may be derived from post-prandial lipoproteins. Eur. J. Clin. Invest.28, 497–504 (1998).
   PubMed Web of Science ®Google Scholar
• Goldstein JL, Ho YK, Brown MS et al. Cholesteryl ester accumulation in macrophages resulting from receptor-mediated uptake and degradation of hypercholesterolemic canine β-very low density lipopropteins. J. Biol. Chem.255, 1839–1848 (1980).
   PubMed Web of Science ®Google Scholar
• Zheng XY, Lui L. Remnant-like lipoproteins particles impair endothelial function: direct and indirect effects on nitric oxide synthase. J. Lipid Res.48, 1673–1680 (2007).
   PubMed Web of Science ®Google Scholar
• Alipour A, van Oostrom AJ, Izraeljan A et al. Leukocyte activation by triglyceride-rich lipoproteins. Arterioscler. Thromb. Vasc. Biol.28, 792–797 (2008).
   PubMed Web of Science ®Google Scholar
• Wang L, Gill R, Pedersen TL et al. Triglyceride-rich lipoprotein lipolysis releases neutral and oxidized FFAs that induce endothelial cell inflammation. J. Lipid Res.50, 204–213 (2009).
   PubMed Web of Science ®Google Scholar
• Sambola A, Osende J, Hathcock J et al. Role of risk factors in the modulation of tissue factor in the modulation of tissue factor activity and blood thrombogenicity. Circulation107, 973–977 (2003).
   PubMed Web of Science ®Google Scholar
• Moyer MP, Tracy RP, Tracy PB et al. Plasma lipoproteins support prothombinase and other procoagulant enzymatic complexes. Arterioscler. Thromb. Vasc. Biol.18, 458–465 (1998).
   Web of Science ®Google Scholar
• Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. N. Engl. J. Med.342, 1792–1801 (2000).
   PubMed Web of Science ®Google Scholar
• Alaupovic P, Mack WJ, Knight-Gibson C et al. The role of triglyceride-rich lipoprotein families in the progression of atherosclerosis lesions as determined by sequential coronary angiography from a controlled clinical trial. Arterioscler. Thromb. Vasc. Biol.17, 715–722 (1997).
   PubMed Web of Science ®Google Scholar
• Gronholdt ML, Nordestgaard BG, Nielsen TG et al. Echolucent carotid arery plaques are associated with elevated levels of fasting and postprandial triglyceride-rich lipoproteins. Stroke27, 2166–2172 (1996).
   PubMed Web of Science ®Google Scholar
• Tiyyagara SR, Smith DA. Standard lipid profile. Clin. Lab. Med.26, 707–732 (2006).
   Google Scholar
• Langsted A, Nordestgaard BG. Nonfasting lipids, lipopropteins and apolipoproteins in individuals with and without diabetes: 58,434 individuals from the Copenhagen General Population Study. Clin Chem57(3), 482–489 (2011).
   PubMed Web of Science ®Google Scholar
• Mora S, Rifai N, Burning JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation118, 993–1001 (2010).
   Google Scholar
• Sniderman A, Couture P, de Graaf J. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. Nat. Rev. Endocrinol.6, 335–346 (2010).
   PubMed Web of Science ®Google Scholar
• Sniderman AD, Williams K, McQueen MJ et al. When is equal not equal? J. Clin. Lipidol.4(2), 83–88 (2010).
   Google Scholar
• Chapman MJ, Redfern JS, McGovern ME et al. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol. Ther.126, 314–345 (2010).
   PubMed Web of Science ®Google Scholar
• Kearney PM, Blackwell L, Collins R et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet371, 117–125 (2008).
   PubMed Web of Science ®Google Scholar
• Miller M, Cannon CP, Murphy SA, Qin J, Ray KK, Braunwald E; PROVE-IT TIMI 22 Investigators. Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE-IT TIMI 22 Trial. J. Am. Coll. Cardiol.51, 724–730 (2008).
   PubMed Web of Science ®Google Scholar
• Faergeman O, Holme I, Fayyad R et al. Steering Committees of IDEAL and TNT Trials. Plasma triglycerides and cardiovascular events in the treating to new targets and incremental decrease in end-points through aggressive lipid lowering trials of statins in patients with coronary artery disease. Am. J. Cardiol.104, 459–463 (2009).
   PubMed Web of Science ®Google Scholar
• Rossebo AB, Pedersen TR, Boman K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med.359, 1343–1356 (2008).
   PubMed Web of Science ®Google Scholar
• Fleg JL, Mete M, Howard BV et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in Type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J. Am. Coll. Cardiol.52, 2198–2205 (2008).
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Reith C et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet377(9784), 2181–2192 (2011).
   PubMed Web of Science ®Google Scholar
• Staels B, Dallongeville J, Auwerx J et al. Metabolism of action of fibrates in lipid and lipid metabolism. Circulation98, 2088–2093 (1998).
   PubMed Web of Science ®Google Scholar
• Marx N, Duez H, Fruchart JC et al. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ. Res.94(9), 1168–1178 (2004).
   PubMed Web of Science ®Google Scholar
• Jun M, Foote C, Lv J et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet375, 1875–1884 (2010).
   PubMed Web of Science ®Google Scholar
• The FIELD Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with Type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet366, 1849–1861 (2005).
   PubMed Web of Science ®Google Scholar
• Manninen V, Elo MO, Frick MH et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA.260, 641–651 (1998).
   Google Scholar
• The BIP Study Group. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Bezafibrate Infarction Prevention (BIP) Study. Circulation102, 21–27 (2000).
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch. Intern. Med.162, 2597–2604 (2002).
   PubMed Web of Science ®Google Scholar
• Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet370, 1687–1697 (2007).
   PubMed Web of Science ®Google Scholar
• Rajamani K, Colman PG, Li LP et al. Effect of fenofibrate on amputation events in people with Type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet373, 1780–1788 (2009).
   PubMed Web of Science ®Google Scholar
• The ACCORD Study Group and ACCORD Eye Group. Effects of medical therapies on retinopathy progression in Type 2 diabetes, N. Engl. J. Med.363, 233–244 (2010).
   PubMed Web of Science ®Google Scholar
• Ismail-Beigi F, Craven T, Banerji MA et al.; for the ACCORD Trial Group. Effect of Intensive treatment of hyperglycaemia on microvascular outcome in Type 2 diabetes: an analysis of the ACCORD randomized trial. Lancet376, 419–430 (2010).
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur. Heart28, 2375–2414 (2007).
   PubMed Web of Science ®Google Scholar
• Davidson MH, Armani A, McKenny JM et al. Safety considerations with fibrate therapy. Am. J. Cardiol.99(Suppl.), 3C–18C (2007).
   PubMed Web of Science ®Google Scholar
• Canner PL, Berge KG, Wenger NK et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J. Am. Coll. Cardiol.8, 1245–1255 (1986).
   PubMed Web of Science ®Google Scholar
• Canner PL, Furberg CD, Terrin ML et al. Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am. J. Cardiol.95, 254–257 (2005).
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao XQ, Chait A et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N. Engl. J. Med.345(22), 1583–1592 (2001).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ et al. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation110, 3512–3517 (2004).
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek EJ et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N. Engl. J. Med.361, 2113–2122 (2009).
   PubMed Web of Science ®Google Scholar
• Guyton JR, Bays HE. Safety Considerations with Niacin Therapy. Am. J. Cardiol.99(Suppl.), 22C–31C (2007).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with Type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch. Intern. Med.162, 1568–1576 (2002).
   PubMed Web of Science ®Google Scholar
• Goldberg RB, Jacobson TA. Effects of niacin on glucose control in patients with dyslipidemia. Mayo Clin. Proc.83, 470–478 (2008).
   PubMed Web of Science ®Google Scholar
• Jump DB. N-3 polyunsaturated fatty acid regulation of hepatic gene transcription. Curr. Opin. Lipodol.19, 242–247 (2008).
   PubMed Web of Science ®Google Scholar
• Durrington PN, Bhatnagar D, Mackness MI et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart85, 544–548 (2001).
   PubMed Web of Science ®Google Scholar
• Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet354, 447–455 (1999).
   PubMed Web of Science ®Google Scholar
• Kromhout D, Giltay EJ, Geleijnse JM. n-3 fatty acids and cardiovascular events after myocardial infarction. N. Engl. J. Med.363, 2015–2026 (2010).
   PubMed Web of Science ®Google Scholar
• Yokoyama M, Origasa H, Matsuzaki M et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet369, 1090–1098 (2007).
   PubMed Web of Science ®Google Scholar
• Rauch B, Schiele R, Schneider S et al. OMEGA, randomised, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation122, 2152–2159 (2010).
   PubMed Web of Science ®Google Scholar
• Saravanan P, Davidson NC, Schmidt EB et al. Cardiovascular effects of marine omega-3 fatty acids. Lancet375, 540–550 (2010).
   PubMed Web of Science ®Google Scholar
• Taskinen M-R, Barter PJ, Ehnholm C et al.; on behalf of the FIELD study investigators. Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with Type 2 diabetes. Diabetologia53, 223–229 (2010).
   Google Scholar
• Su JW, Nzekwu MM, Cabezas MC, Redgrave T, Proctor SD. Methods to assess impaired post-prandial metabolism and the impact for early detection of cardiovascular disease risk. Eur. J. Clin. Invest.39(9), 741–754 (2009).
   PubMed Web of Science ®Google Scholar
• Fonesca VA, Handelsman Y, Staels B. Colesevelam lowers glucose and lipid levels in Type 2 diabetes: the clinical evidence. Diabetes Obes. Metab.12, 384–392 (2010).
   Google Scholar
• Kastelein JJP, Van der Steeg WA, Holme I et al. Lipids, apolipoproteins and their ratios in relation to cardiovascular events with statin treatment. Circulation117, 3002–3009 (2008).
   PubMed Web of Science ®Google Scholar
• Hamilton SJ, Chen GT, Davis TM, Stuckley BG, Watts GF. Hypertriglyceridaemia in stratin treated Type 2 diabetic patients. Prac. Diabetes28, 257–260 (2011).
   Google Scholar
• Bates TR, Connaughton VM, Watts GF. Non-adherence to statin therapy: a major challenge for preventive cardiology. Expert Opin. Pharmacother.10, 2973–2985 (2009).
   PubMed Web of Science ®Google Scholar
• Miller M, Stone NJ, Ballantyne C et al. Triglycerides and cardiovascular disease. A Scientific Statement from the American Heart Association. Circulation123(20), 2292–2333 (2011).
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Ginsberg HN, Amarenco P et al.; for the European Atherosclerosis Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoproteins cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J.32(11), 1345–1361 (2011).
   PubMed Web of Science ®Google Scholar
• Reiner Z, Catapano AL, De Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J.32(14), 1769–1818 (2011).
   PubMed Web of Science ®Google Scholar